Profile data is unavailable for this security.
About the company
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using proprietary platforms. Its product pipeline includes ongoing human clinical trials for a Covid-19 vaccine and a gene-directed therapy against advanced head and neck cancers. Its additional research and development programs include preventive vaccines against Mpox and smallpox, hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan and Marburg), Zika virus and malaria, as well as immunotherapies for multiple solid tumors. The Company’s portfolio of wholly owned, co-owned, and in-licensed intellectual property, stands at over 155 granted or pending patent applications spread over 24 patent families. Its product candidate includes GEO-CM04S1, GEO-CM02, Gedeptin, MVA-VLP-MUC1, GEO-ZM02 and others. Its lead infectious disease candidate is GEO-CM04S1, a COVID-19 vaccine targeting high-risk immunocompromised patient populations.
- Revenue in USD (TTM)3.35m
- Net income in USD-25.31m
- Incorporated2008
- Employees17.00
- LocationGeoVax Labs Inc1955 Lake Park Drive, Suite 300SMYRNA 30080United StatesUSA
- Phone+1 (678) 384-7220
- Fax+1 (302) 655-5049
- Websitehttps://www.geovax.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| InMed Pharmaceuticals Inc | 4.51m | -7.66m | 2.56m | 13.00 | -- | 0.2565 | -- | 0.5681 | -4.08 | -4.08 | 1.72 | 3.42 | 0.4577 | 3.09 | 20.23 | -- | -77.84 | -87.37 | -93.34 | -107.49 | 29.73 | -- | -170.07 | -356.16 | 5.30 | -- | 0.00 | -- | 7.50 | -- | -6.34 | -- | -- | -- |
| BioRestorative Therapies Inc | 383.40k | -12.67m | 2.58m | 11.00 | -- | 1.04 | -- | 6.72 | -1.48 | -1.48 | 0.0447 | 0.2766 | 0.0379 | -- | 4.30 | 34,854.55 | -125.35 | -149.02 | -207.73 | -188.71 | 93.34 | -- | -3,304.77 | -11,837.37 | -- | -- | 0.00 | -- | 175.03 | 25.27 | 13.81 | -- | 24.41 | -- |
| Oragenics Inc | 0.00 | -10.90m | 2.74m | 3.00 | -- | 0.2756 | -- | -- | -17.15 | -17.15 | 0.00 | 2.38 | 0.00 | -- | -- | 0.00 | -121.78 | -113.47 | -168.95 | -126.49 | -- | -- | -- | -34,218.60 | -- | -14.92 | 0.0386 | -- | -100.00 | -- | 48.84 | -- | -- | -- |
| Propanc Biopharma Inc | 0.00 | -63.41m | 2.85m | 1.00 | -- | 0.1976 | -- | -- | -45.47 | -45.47 | 0.00 | 1.08 | 0.00 | -- | -- | 0.00 | -702.98 | -- | -1,223.40 | -- | -- | -- | -- | -- | -- | -56.99 | 0.0422 | -- | -- | -- | -2,826.43 | -- | -- | -- |
| Enzolytics Inc | 0.00 | -119.19k | 2.90m | 2.00 | -- | -- | -- | -- | -0.106 | -0.106 | 0.00 | -1.04 | 0.00 | -- | -- | -- | -369.52 | -- | -- | -- | -- | -- | -- | -- | -- | -4.30 | -- | -- | -100.00 | -- | -9.35 | -- | -- | -- |
| Geovax Labs Inc | 3.35m | -25.31m | 2.91m | 17.00 | -- | 0.4068 | -- | 0.8677 | -49.15 | -49.15 | 5.86 | 4.13 | 0.3759 | -- | 12.25 | 197,268.20 | -283.68 | -128.86 | -377.44 | -172.81 | -- | -- | -754.69 | -1,385.19 | -- | -- | 0.00 | -- | -- | 27.45 | 3.75 | -- | 22.10 | -- |
| Enveric Biosciences Inc | 0.00 | -11.25m | 2.92m | 5.00 | -- | 0.1326 | -- | -- | -94.63 | -94.63 | 0.00 | 15.83 | 0.00 | -- | -- | 0.00 | -212.68 | -146.94 | -262.78 | -198.90 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 45.16 | -- | -- | -- |
| Shuttle Pharmaceuticals Holdings Inc | 0.00 | -10.71m | 2.98m | 9.00 | -- | 0.9837 | -- | -- | -25.86 | -25.86 | 0.00 | 1.13 | 0.00 | -- | -- | 0.00 | -507.78 | -- | -3,614.50 | -- | -- | -- | -- | -- | -- | -- | 0.2305 | -- | -- | -- | -38.71 | -- | -- | -- |
| Dermata Therapeutics Inc | 0.00 | -8.85m | 3.08m | 8.00 | -- | 0.2751 | -- | -- | -28.37 | -28.37 | 0.00 | 4.69 | 0.00 | -- | -- | 0.00 | -150.49 | -136.32 | -203.36 | -201.56 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -57.64 | -- | -- | -- |
| Psyence Biomedical Ltd | -100.00bn | -100.00bn | 3.16m | 12.00 | -- | 0.0125 | -- | -- | -- | -- | -- | 247.64 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 101.98 | -- | -- | -- |
| Adial Pharmaceuticals Inc | 0.00 | -8.05m | 3.17m | 5.00 | -- | 0.6032 | -- | -- | -23.22 | -23.22 | 0.00 | 4.72 | 0.00 | -- | -- | 0.00 | -130.16 | -205.76 | -155.01 | -274.10 | -- | -- | -- | -- | -- | -27.38 | 0.00 | -- | -- | -- | -88.48 | -- | -- | -- |
| ProtoKinetix, Inc. | 0.00 | -376.18k | 3.21m | 0.00 | -- | 12.77 | -- | -- | -0.001 | -0.001 | 0.00 | 0.0006 | 0.00 | -- | -- | -- | -78.62 | -530.88 | -117.20 | -607.05 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 12.34 | -- | 18.34 | -- |
| GRI Bio Inc | 0.00 | -11.96m | 3.34m | 4.00 | -- | 0.1914 | -- | -- | -248.19 | -248.19 | 0.00 | 12.07 | 0.00 | -- | -- | 0.00 | -166.00 | -190.54 | -236.14 | -330.83 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -18.17 | -- | 8.45 | -- |
| Holder | Shares | % Held |
|---|---|---|
| L1 Capital Global, Inc.as of 02 Jul 2025 | 59.00k | 3.41% |
| Sabby Management LLCas of 30 Sep 2025 | 26.46k | 1.53% |
| Renaissance Technologies LLCas of 31 Dec 2025 | 24.26k | 1.40% |
| Jane Street Capital LLCas of 31 Dec 2025 | 23.26k | 1.34% |
| Armistice Capital LLCas of 30 Sep 2025 | 21.36k | 1.23% |
| Abante Asesores Gesti�n SGIIC SAas of 31 Dec 2025 | 8.58k | 0.50% |
| Geode Capital Management LLCas of 31 Dec 2025 | 8.28k | 0.48% |
| HRT Financial LPas of 31 Dec 2025 | 7.41k | 0.43% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 5.07k | 0.29% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 4.70k | 0.27% |
